IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.82+0.00 (+0.49%)
Close on Nov 17, 2026Market cap $8.08MP/E –Yield –
IN8bio total assets
Total assets on the balance sheet at the end of each period.
IN8bio's total assets was $21.75M at Jun 30, 2026. For fiscal 2025 it was $32.28M, up 54.1% from the year before. The highest annual figure on record is $42.22M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.28M | +54.1% |
| FY2024 | Dec 31, 2024 | $20.94M | -37.9% |
| FY2023 | Dec 31, 2023 | $33.71M | +2.0% |
| FY2022 | Dec 31, 2022 | $33.04M | -21.8% |
| FY2021 | Dec 31, 2021 | $42.22M | +101.9% |
| FY2020 | Dec 31, 2020 | $20.91M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $21.75M | +12.3% |
| Q1 FY2026 | Mar 31, 2026 | $26.27M | +32.2% |
| Q4 FY2025 | Dec 31, 2025 | $32.28M | +54.1% |
| Q3 FY2025 | Sep 30, 2025 | $16.77M | +5.0% |
| Q2 FY2025 | Jun 30, 2025 | $19.37M | -13.9% |
| Q1 FY2025 | Mar 31, 2025 | $19.87M | -41.1% |
| Q4 FY2024 | Dec 31, 2024 | $20.94M | -20.1% |
| Q3 FY2024 | Sep 30, 2024 | $15.97M | -46.3% |
| Q2 FY2024 | Jun 30, 2024 | $22.50M | -8.8% |
| Q4 FY2023 | Dec 31, 2023 | $33.71M | +2.0% |
| Q3 FY2023 | Sep 30, 2023 | $26.21M | -31.7% |
| Q2 FY2023 | Jun 30, 2023 | $29.72M | -4.1% |
| Q1 FY2023 | Mar 31, 2023 | $24.68M | -32.5% |
| Q4 FY2022 | Dec 31, 2022 | $33.04M | -21.8% |
| Q3 FY2022 | Sep 30, 2022 | $38.38M | -18.6% |
| Q2 FY2022 | Jun 30, 2022 | $30.99M | +76.4% |
| Q1 FY2022 | Mar 31, 2022 | $36.54M | +74.7% |
| Q4 FY2021 | Dec 31, 2021 | $42.22M | – |
| Q3 FY2021 | Sep 30, 2021 | $47.13M | – |
| Q2 FY2021 | Jun 30, 2021 | $17.56M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.91M | – |
See a number that looks wrong?